Core Viewpoint - Huaheng Biological is a leading biomanufacturing company specializing in amino acids and their derivatives, with a focus on R&D, production, and sales in the food and feed additive sector [1] Group 1: Business Performance - For Q3 2025, Huaheng Biological reported revenue of 2.194 billion yuan, ranking 8th in the industry out of 24 companies, with the industry leader, Meihua Biological, generating 18.215 billion yuan [2] - The net profit for the same period was 159 million yuan, placing the company 9th in the industry, while the top performer, Xinheng, achieved a net profit of 5.354 billion yuan [2] - Year-on-year, the company’s revenue increased by 42.5%, while the net profit saw a slight decline of 1.3% [5] Group 2: Financial Ratios - As of Q3 2025, Huaheng Biological's debt-to-asset ratio stood at 52.96%, higher than the industry average of 28.46%, although it has improved from 60.56% in the previous year [3] - The gross profit margin was reported at 23.55%, below the industry average of 28.77%, and down from 28.13% in the previous year, indicating a need for improvement in profitability [3] Group 3: Leadership and Shareholder Information - The chairman and general manager, Guo Henghua, saw her salary increase from 1.026 million yuan in 2023 to 1.754 million yuan in 2024, an increase of 728,000 yuan [4] - As of September 30, 2025, the number of A-share shareholders increased by 23.84% to 10,200, while the average number of shares held per shareholder decreased by 19.25% to 24,500 [5]

Investment Rating - The report maintains a "Buy" rating for the company [8][9][20] Core Views - The company reported a revenue of 21.9 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 42.5%. The net profit attributable to shareholders was 1.7 billion yuan, a slight decrease of 1.3% year-on-year, while the net profit excluding non-recurring items was also 1.7 billion yuan, up 0.8% year-on-year [2][6] - In Q3 alone, the company achieved a revenue of 7.0 billion yuan, which is a 34.7% increase year-on-year but a 12.2% decrease quarter-on-quarter. The net profit attributable to shareholders for Q3 was 0.53 billion yuan, up 161.2% year-on-year but down 17.3% quarter-on-quarter [2][6] - The company is a leading player in the biomanufacturing sector with high technical barriers, and the future release of new products is promising. Projected net profits for 2025-2027 are 2.5 billion, 3.6 billion, and 5.1 billion yuan respectively [8][9] Summary by Sections Financial Performance - For the first three quarters of 2025, the company achieved a total revenue of 21.9 billion yuan, a 42.5% increase year-on-year, and a net profit of 1.7 billion yuan, down 1.3% year-on-year. The net profit excluding non-recurring items was also 1.7 billion yuan, up 0.8% year-on-year [2][6] - In Q3, the company reported a revenue of 7.0 billion yuan, a 34.7% increase year-on-year, and a net profit of 0.53 billion yuan, up 161.2% year-on-year [2][6] Market Dynamics - The average price of refrigerants continued to rise in Q3, with a slight decrease in sales volume quarter-on-quarter. The company sold 76,000 tons of refrigerants in Q3, a decrease of 10.6% year-on-year and 10.3% quarter-on-quarter, with a tax-inclusive average price of 43,000 yuan per ton, up 52.6% year-on-year [7][12] - The company’s profit margins saw a slight decline in Q3, with a gross profit margin of 22.4%, up 1.0 percentage points year-on-year but down 1.6 percentage points quarter-on-quarter [7][12] Future Outlook - The company is expected to benefit from the ongoing growth in the refrigerant industry, with new product launches anticipated to drive future revenue growth. The company is also investing in biobased new materials and has established partnerships to enhance its product offerings [12][8] - The projected revenues for 2025-2027 are 50.3 billion, 67.8 billion, and 86.7 billion yuan respectively, indicating strong growth potential [9][8]

Core Viewpoint - Anhui Huaheng Biotechnology Co., Ltd. has reported significant growth in its financial performance for Q3 2025, indicating strong operational momentum and a focus on research and innovation [1][2] Financial Performance - In Q3, the company's operating revenue reached 704 million yuan, representing a year-on-year increase of 34.73% [1] - The net profit attributable to shareholders was 52.73 million yuan, showing a remarkable year-on-year growth of 161.22% [1] - The net profit after deducting non-recurring gains and losses was 52.21 million yuan, reflecting a year-on-year increase of 187.98% [1] - For the first three quarters, the total operating revenue amounted to 2.194 billion yuan, marking a year-on-year growth of 42.53% [1] Research and Development - The company emphasizes research and innovation, with internal teams focused on market demands and developing cutting-edge synthetic biology technologies [1] - Multiple high-end research platforms have been established, including independent research platforms, strategic cooperation platforms, and joint laboratories with major research institutes and universities [1] - External research teams provide comprehensive support in areas such as strain construction, technology expansion, and innovation management, laying a solid foundation for product innovation and sustainable development [1] Strategic Initiatives - To enhance brand influence and core competitiveness, the company has officially submitted an application for listing on the main board of the Hong Kong Stock Exchange [1] - Successful issuance of H-shares is expected to help the company leverage international capital market resources, optimize capital structure, and broaden financing channels [2] - This move is aligned with the company's global development strategy aimed at achieving stable performance growth [2]

Core Viewpoint - Huaheng Biological has demonstrated significant growth in its financial performance for Q3 2025, with a notable increase in revenue and net profit, positioning itself as a leader in the bio-based product market [1][2][3] Financial Performance - In Q3 2025, the company achieved revenue of 704 million yuan, a year-on-year increase of 34.73% - The net profit attributable to shareholders reached 52.73 million yuan, up 161.22% year-on-year - The net profit after deducting non-recurring items was 52.21 million yuan, reflecting a growth of 187.98% - The net cash flow from operating activities was 40.01 million yuan, an increase of 84.95% year-on-year - For the first three quarters, total revenue amounted to 2.194 billion yuan, representing a year-on-year growth of 42.53% [1] Market Position and Product Development - Huaheng Biological is recognized as one of the most comprehensive companies in the commercial application of bio-based products through synthetic biology technology - The company is the first globally to industrialize the anaerobic fermentation method for a series of amino acids, including L-Alanine and L-Valine - By 2024, the company holds the largest market share globally for L-Alanine and L-Valine [1][2] Global Expansion and Strategic Initiatives - The company has established a comprehensive product portfolio, including amino acids, vitamins, and other bio-based products, widely used across various industries such as animal nutrition, personal care, food and beverage, advanced materials, and plant nutrition - As of mid-2025, Huaheng Biological has formed stable long-term partnerships with over 768 clients across 85 countries in Asia, Europe, and the Americas, with some relationships lasting over 10 years - The global bio-based product market is expected to grow at a compound annual growth rate of 11.3% from 2024 to 2030, presenting significant growth opportunities for Huaheng Biological [2] Research and Development - The company places a strong emphasis on R&D innovation, with internal teams focused on market needs and developing cutting-edge synthetic biology technologies - Multiple high-end research platforms have been established, including independent R&D platforms, strategic cooperation platforms, and joint laboratories with major research institutions and universities - External research teams provide comprehensive support in areas such as strain construction, technology expansion, and innovation management, laying a solid foundation for product innovation and sustainable development [2] Listing and Capital Strategy - Recently, Huaheng Biological submitted an application for listing on the main board of the Hong Kong Stock Exchange to further its globalization strategy and consolidate its industry-leading position - A successful H-share issuance would help the company leverage international capital market resources, optimize its capital structure, and broaden financing channels to support stable growth [3]

Core Insights - Huaheng Biological (688639.SH) reported a total operating revenue of 2.194 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 42.53% [1] - The net profit attributable to shareholders of the parent company was 168 million yuan, showing a year-on-year decrease of 1.34% [1] - The basic earnings per share stood at 0.67 yuan [1]

Group 1 - The company announced the convening of its second employee representative assembly for 2025 on October 27, 2025 [1] - Mao Jianwen has been elected as the employee representative director of the company's fifth board of directors [1]

独立董事候选人声明与承诺 （二）中国证监会《上市公司独立董事管理办法》、上海证 券交易所自律监管规则以及公司章程有关独立董事任职资格和 条件的相关规定； （三）其他法律法规、部门规章、规范性文件和上海证券 交易所规定的情形。 三、本人具备独立性，不属于下列情形： （一）在上市公司或者其附属企业任职的人员及其配偶、 父母、子女、主要社会关系（主要社会关系是指兄弟姐妹、兄 弟姐妹的配偶、配偶的父母、配偶的兄弟姐妹、子女的配偶、 子女配偶的父母等）； （二）直接或者间接持有上市公司已发行股份 1%以上或者 是上市公司前十名股东中的自然人股东及其配偶、父母、子女； （三）在直接或者间接持有上市公司已发行股份 5%以上的 股东或者在上市公司前五名股东任职的人员及其配偶、父母、 子女； 本人陈继忠，已充分了解并同意由提名人安徽华恒生物科 技股份有限公司董事会提名为安徽华恒生物科技股份有限公司 第五届董事会独立董事候选人。本人公开声明，本人具备独立 董事任职资格，保证不存在任何影响本人担任安徽华恒生物科 技股份有限公司独立董事独立性的关系，具体声明并承诺如下： 一、本人具备上市公司运作的基本知识，熟悉相关法律、 行政法规、 ...

本人吴林，已充分了解并同意由提名人安徽华恒生物科技 股份有限公司董事会提名为安徽华恒生物科技股份有限公司第 五届董事会独立董事候选人。本人公开声明，本人具备独立董 事任职资格，保证不存在任何影响本人担任安徽华恒生物科技 股份有限公司独立董事独立性的关系，具体声明并承诺如下： 一、本人具备上市公司运作的基本知识，熟悉相关法律、 行政法规、部门规章及其他规范性文件，具有 5 年以上法律、 经济、会计、财务、管理或者其他履行独立董事职责所必需的 工作经验。 二、本人任职资格符合下列法律、行政法规和部门规章以 及公司规章的要求： （一）《中华人民共和国公司法》关于董事任职资格的规定； （二）中国证监会《上市公司独立董事管理办法》、上海证 券交易所自律监管规则以及公司章程有关独立董事任职资格和 条件的相关规定； （三）其他法律法规、部门规章、规范性文件和上海证券 交易所规定的情形。 三、本人具备独立性，不属于下列情形： （一）在上市公司或者其附属企业任职的人员及其配偶、 父母、子女、主要社会关系（主要社会关系是指兄弟姐妹、兄 弟姐妹的配偶、配偶的父母、配偶的兄弟姐妹、子女的配偶、 独立董事候选人声明与承诺 子女配偶的父 ...

独立董事提名人声明与承诺 提名人安徽华恒生物科技股份有限公司董事会，现提名 WANG FUCAI（王富才）先生为安徽华恒生物科技股份有限公 司第五届董事会独立董事候选人，并已充分了解被提名人职业、 学历、职称、详细的工作经历、全部兼职、有无重大失信等不 良记录等情况。被提名人已同意出任安徽华恒生物科技股份有 限公司第五届董事会独立董事候选人（参见该独立董事候选人 声明）。提名人认为，被提名人具备独立董事任职资格，与安徽 华恒生物科技股份有限公司之间不存在任何影响其独立性的关 系，具体声明并承诺如下： 一、被提名人具备上市公司运作的基本知识，熟悉相关法 律、行政法规、规章及其他规范性文件，具有 5 年以上法律、 经济、会计、财务、管理或者其他履行独立董事职责所必需的 工作经验。 二、被提名人任职资格符合下列法律、行政法规和部门规 章的要求： （一）《中华人民共和国公司法》关于董事任职资格的规定； （二）中国证监会《上市公司独立董事管理办法》、上海证 券交易所自律监管规则以及公司章程有关独立董事任职资格和 条件的相关规定； （三）其他法律法规、部门规章、规范性文件和上海证券 交易所规定的情形。 三、被提名人具备独 ...

关于选举第五届董事会职工代表董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 安徽华恒生物科技股份有限公司（以下简称"公司"）第四届董事会任期 即将届满，根据《中华人民共和国公司法》（以下简称《公司法》）《上海证 券交易所科创板股票上市规则》《上海证券交易所科创板上市公司自律监管指 引第1号——规范运作》等法律法规、规范性文件以及《公司章程》等规定，公 司于2025年10月27日召开了2025年第二次职工代表大会，选举MAO JIANWEN （毛建文）先生为公司第五届董事会职工代表董事，与公司2025年第三次临时 股东会选举产生的董事共同组成公司第五届董事会，任期与公司第五届董事会 任期一致。上述第五届董事会职工代表董事简历详见附件。 上述职工代表董事符合相关法律、行政法规、规范性文件对董事任职资格 的要求，不存在《公司法》《公司章程》规定的不得担任公司董事的情形，未 曾受到中国证监会的行政处罚或证券交易所惩戒，不存在证券交易所公开认定 为不适合担任上市公司董事的情形。 证券代码:688639 证券简称:华恒生物 ...